Icon

ROMVIMZA (NDA219304)- (14MG,20MG,30MG)

VIMSELTINIB DECIPHERA PHARMS
14MG,20MG,30MG
No No
2040-Feb-03 2030-Feb-14
None None
None No
ROMVIMZA is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
0 0 0
Total Other Developers None
Drugs with Suitability No
14MG ** ** - - -
20MG ** ** - - -
30MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.